A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China.
Phase of Trial: Phase IV
Latest Information Update: 11 Dec 2013
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 07 Jun 2017 Biomarkers information updated
- 06 Jan 2012 Planned end date changed from 1 Oct 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 06 Jan 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.